Jong-Ho Nam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jong-Ho Nam has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Jang-Won Son
Division of Cardiology, Yeungnam University Medical Center, Yeungnam University College of Medicine , Daegu
13 shared publications - Ung Kim
Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea
11 shared publications - Dong-Gu Shin
Division of Cardiology, Yeungnam University College of Medicine, Daegu, Korea
8 shared publications - Jong-Seon Park
Division of Cardiology, Yeungnam University Medical Center, Daegu, Republic of Korea
8 shared publications - Kang-Un Choi
Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea
8 shared publications Chan-Hee Lee
Division of Cardiology, Yeungnam University Medical Center, Daegu, South Korea (Drs J. Park, U. Kim, H-J. Kim, Choi, Nam, Lee, Son, and J-S. Park)
7 shared publications
Latest Publications
- 22 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (9) , 1644-1654
Echocardiographic drag effect index and its association with response to mavacamten in obstructive hypertrophic cardiomyopathy
Aims: Despite mavacamten’s effect on left ventricular outflow tract (LVOT) obstruction, clinical response is heterogeneous. Considering the central role of systolic anterior motion (SAM) in obstruction, we examined whether mitral geometry and SAM-related echocardiographic indices correlate with this variability in obstructive hypertrophic cardiomyopathy (HCM) patients. Methods and results: A total of 128 patients with obstructive HCM were included in this multi-centre observational study. The SAM-related echocardiographic parameters—including anterior and posterior leaflet lengths, residual leaflet length (RL), protrusion height, and aortomitral angle (α)—were measured. A drag effect index was quantified by sin(α) × RL. Clinical response was defined as achieving a lowest observed Valsalva-induced LVOT gradient of less than 30 mmHg at any point during the 12-week follow-up period. Among the 128 patients, 33 (25.8%) were non-responders. Non-responders had a smaller α (115.3 ± 8.3° vs. 125.7 ± 9.9°; P < 0.001), longer RL (1.1 ± 0.2 vs. 0.8 ± 0.3, P < 0.001), and higher drag effect index values (sin(α) × RL; 1.0 ± 0.2 vs. 0.7 ± 0.3; P < 0.001). Multivariable logistic regression identified resting LVOT gradient, α, and drag effect index as independent factors associated with non-response. Receiver operating characteristic analysis demonstrated moderate discriminative ability for α [area under the curve (AUC) 0.787], RL (AUC 0.754), and strong discriminatory ability for the drag effect index (AUC 0.825), with the drag effect index providing the highest overall accuracy (73%). Conclusion: Drag-based echocardiographic indices offered high discriminatory performance for mavacamten response. Integrating these patient-specific metrics into routine assessment provides valuable pathophysiological insights into SAM mechanisms in obstructive HCM.
- 22 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (9) , 1644-1654
Echocardiographic drag effect index and its association with response to mavacamten in obstructive hypertrophic cardiomyopathy
Aims: Despite mavacamten’s effect on left ventricular outflow tract (LVOT) obstruction, clinical response is heterogeneous. Considering the central role of systolic anterior motion (SAM) in obstruction, we examined whether mitral geometry and SAM-related echocardiographic indices correlate with this variability in obstructive hypertrophic cardiomyopathy (HCM) patients. Methods and results: A total of 128 patients with obstructive HCM were included in this multi-centre observational study. The SAM-related echocardiographic parameters—including anterior and posterior leaflet lengths, residual leaflet length (RL), protrusion height, and aortomitral angle (α)—were measured. A drag effect index was quantified by sin(α) × RL. Clinical response was defined as achieving a lowest observed Valsalva-induced LVOT gradient of less than 30 mmHg at any point during the 12-week follow-up period. Among the 128 patients, 33 (25.8%) were non-responders. Non-responders had a smaller α (115.3 ± 8.3° vs. 125.7 ± 9.9°; P < 0.001), longer RL (1.1 ± 0.2 vs. 0.8 ± 0.3, P < 0.001), and higher drag effect index values (sin(α) × RL; 1.0 ± 0.2 vs. 0.7 ± 0.3; P < 0.001). Multivariable logistic regression identified resting LVOT gradient, α, and drag effect index as independent factors associated with non-response. Receiver operating characteristic analysis demonstrated moderate discriminative ability for α [area under the curve (AUC) 0.787], RL (AUC 0.754), and strong discriminatory ability for the drag effect index (AUC 0.825), with the drag effect index providing the highest overall accuracy (73%). Conclusion: Drag-based echocardiographic indices offered high discriminatory performance for mavacamten response. Integrating these patient-specific metrics into routine assessment provides valuable pathophysiological insights into SAM mechanisms in obstructive HCM.
- Open Access
- 19 December 2024
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 42, 18
Complete or incomplete revascularization in patients with left main culprit lesion acute myocardial infarction with multivessel disease: a retrospective observational study
Background: Complete revascularization has demonstrated better outcomes in patients with acute myocardial infarction (AMI) and multivessel disease. However, in the case of left main (LM) culprit lesion AMI with multivessel disease, there is limited evidence to suggest that complete revascularization is better.Methods: We reviewed 16,831 patients in the Korea Acute Myocardial Infarction Registry who were treated from July 2016 to June 2020, and 399 patients were enrolled with LM culprit lesion AMI treated with percutaneous coronary intervention. We categorized the patients as those treated with complete revascularization (n=295) or incomplete revascularization (n=104). The study endpoint was major adverse cardiac and cerebrovascular events (MACCE), a composite of all-cause death, myocardial infarction, ischemia-driven revascularization, stent thrombosis, and stroke. We performed propensity score matching (PSM) and analyzed the incidence of MACCE at 1 year.Results: After PSM, the two groups were well balanced. There was no significant difference between the two groups in MACCE at 1 year (12.1% vs. 15.2%; hazard ratio, 1.28; 95% confidence interval, 0.60–2.74; p=0.524) after PSM. The components of MACCE and major bleeding were also not significantly different.Conclusion: There was no significant difference in clinical outcomes between the groups treated with complete or incomplete revascularization for LM culprit lesion AMI with multivessel disease.
- 19 December 2024
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 42, 18
Open AccessComplete or incomplete revascularization in patients with left main culprit lesion acute myocardial infarction with multivessel disease: a retrospective observational study
Background: Complete revascularization has demonstrated better outcomes in patients with acute myocardial infarction (AMI) and multivessel disease. However, in the case of left main (LM) culprit lesion AMI with multivessel disease, there is limited evidence to suggest that complete revascularization is better.Methods: We reviewed 16,831 patients in the Korea Acute Myocardial Infarction Registry who were treated from July 2016 to June 2020, and 399 patients were enrolled with LM culprit lesion AMI treated with percutaneous coronary intervention. We categorized the patients as those treated with complete revascularization (n=295) or incomplete revascularization (n=104). The study endpoint was major adverse cardiac and cerebrovascular events (MACCE), a composite of all-cause death, myocardial infarction, ischemia-driven revascularization, stent thrombosis, and stroke. We performed propensity score matching (PSM) and analyzed the incidence of MACCE at 1 year.Results: After PSM, the two groups were well balanced. There was no significant difference between the two groups in MACCE at 1 year (12.1% vs. 15.2%; hazard ratio, 1.28; 95% confidence interval, 0.60–2.74; p=0.524) after PSM. The components of MACCE and major bleeding were also not significantly different.Conclusion: There was no significant difference in clinical outcomes between the groups treated with complete or incomplete revascularization for LM culprit lesion AMI with multivessel disease.
- Open Access
- 4 March 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (3) , e24248
Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus
Background: Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have been demonstrated to decrease cardiovascular adverse events. However, there is little real‐world clinical evidence regarding a direct comparison between dapagliflozin and empagliflozin in patients with diabetes mellitus (DM).Hypothesis: A difference in the cardiovascular efficancy of dapagliflozin versus empagliflozin in DM patients was anticipated, aiming to guide the optimal choice of SGLT2 inhibitors based on cardiovascular outcomes.Methods: From 2014 to 2020, a total of 1549 patients with DM who were prescribed SGLT2 inhibitors such as dapagliflozin or empagliflozin were retrospectively enrolled. We categorized the study population into two groups: dapagliflozin (n = 981) and empagliflozin group (n = 568). The primary endpoint was major adverse cardiovascular events (MACE), defined as a composite of all‐cause death, myocardial infarction (MI), stroke, or hospitalization for heart failure (HF) over a 3‐year period.Results: Propensity‐score matching was performed (537 patients in each group). The mean age and hemoglobin A1c were 58.2 ± 13.0 years and 8.4 ± 1.7%, respectively. There was no significant difference between the dapagliflozin and empagliflozin groups in the risk of MACE (3.7% vs. 4.8%, hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.73–2.35; p = 0.349). Furthermore, there were no differences between the two groups in secondary endpoints including all‐cause death, MI, stroke, and hospitalization for HF. Prior MI and history of HF were independent predictors of MACE.Conclusions: Dapagliflozin and empagliflozin showed no significant difference of real‐world clinical cardiovascular outcomes in patients with DM over a 3‐year period. Further large randomized clinical trials will be warranted for better evaluation.
- 4 March 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (3) , e24248
Open AccessCardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus
Background: Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have been demonstrated to decrease cardiovascular adverse events. However, there is little real‐world clinical evidence regarding a direct comparison between dapagliflozin and empagliflozin in patients with diabetes mellitus (DM).Hypothesis: A difference in the cardiovascular efficancy of dapagliflozin versus empagliflozin in DM patients was anticipated, aiming to guide the optimal choice of SGLT2 inhibitors based on cardiovascular outcomes.Methods: From 2014 to 2020, a total of 1549 patients with DM who were prescribed SGLT2 inhibitors such as dapagliflozin or empagliflozin were retrospectively enrolled. We categorized the study population into two groups: dapagliflozin (n = 981) and empagliflozin group (n = 568). The primary endpoint was major adverse cardiovascular events (MACE), defined as a composite of all‐cause death, myocardial infarction (MI), stroke, or hospitalization for heart failure (HF) over a 3‐year period.Results: Propensity‐score matching was performed (537 patients in each group). The mean age and hemoglobin A1c were 58.2 ± 13.0 years and 8.4 ± 1.7%, respectively. There was no significant difference between the dapagliflozin and empagliflozin groups in the risk of MACE (3.7% vs. 4.8%, hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.73–2.35; p = 0.349). Furthermore, there were no differences between the two groups in secondary endpoints including all‐cause death, MI, stroke, and hospitalization for HF. Prior MI and history of HF were independent predictors of MACE.Conclusions: Dapagliflozin and empagliflozin showed no significant difference of real‐world clinical cardiovascular outcomes in patients with DM over a 3‐year period. Further large randomized clinical trials will be warranted for better evaluation.
- Open Access
- 1 January 2024
- Published by XMLink in Cardiovascular Imaging Asia
- Vol. 8 (1) , 11-14
Exercise-Induced Vasospastic Angina With Prominent Regional Wall Motion Abnormality
Son BJ, et al. Cardiovasc Imaging Asia. 2024 Jan;8(1):11-14. https://doi.org/10.22468/cvia.2023.00094
- 1 January 2024
- Published by XMLink in Cardiovascular Imaging Asia
- Vol. 8 (1) , 11-14
Open AccessExercise-Induced Vasospastic Angina With Prominent Regional Wall Motion Abnormality
Son BJ, et al. Cardiovasc Imaging Asia. 2024 Jan;8(1):11-14. https://doi.org/10.22468/cvia.2023.00094
- 7 November 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (Suppl_1)
Abstract 16753: Effectiveness of Guideline-Endorsed Low-Density Lipoprotein Cholesterol Reduction Rates in Patients With Prior Percutaneous Coronary Intervention
- 7 November 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (Suppl_1)
Abstract 16753: Effectiveness of Guideline-Endorsed Low-Density Lipoprotein Cholesterol Reduction Rates in Patients With Prior Percutaneous Coronary Intervention
- Open Access
- 31 October 2023
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 40 (4) , 461-465
Differential diagnosis for unusually dilated coronary sinus and right coronary artery incidentally found on echocardiography
- 31 October 2023
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 40 (4) , 461-465
Open AccessDifferential diagnosis for unusually dilated coronary sinus and right coronary artery incidentally found on echocardiography
- Open Access
- 27 October 2023
- Published by Wiley
Clinical Usefulness of Mitral Inflow Doppler Pattern for differential diagnosis of Pulmonary Embolism in Patients with Pulmonary Hypertension
Background : Clinical manifestations of acute pulmonary embolism (PE) vary widely, making it challenging to diagnose. Differential diagnosis is crucial in patients with right ventricular (RV) pressure overload and dyspnea. Transthoracic echocardiography (TTE), although not the gold standard for PE diagnosis, is a valuable tool in differentiating PE in patients with dyspnea, such as pulmonary hypertension (PH), in real-world practice. Methods and Result : Between 2012 and 2019, 269 patients were enrolled based on specific criteria: 1) pulmonary artery systolic pressure >40 mmHg by TTE, 2) PE confirmed by chest contrast CT, and 3) TTE and CT conducted within a 72-hour interval. The study population was categorized into two groups: PE (n=149) and Non-PE (n=120). In the mitral inflow Doppler parameters, the PE group exhibited significantly lower mitral E velocity. The cutoff value of mitral E velocity (AUC 0.865, 95% CI 0.81-0.92, pConclusion : This study suggests that mitral E velocity is an independent predictor for diagnosing PE. The cutoff value of mitral E velocity is a practical tool for ruling out PE in patients with PH in real-world practice.
- 27 October 2023
- Published by Wiley
Open AccessClinical Usefulness of Mitral Inflow Doppler Pattern for differential diagnosis of Pulmonary Embolism in Patients with Pulmonary Hypertension
Background : Clinical manifestations of acute pulmonary embolism (PE) vary widely, making it challenging to diagnose. Differential diagnosis is crucial in patients with right ventricular (RV) pressure overload and dyspnea. Transthoracic echocardiography (TTE), although not the gold standard for PE diagnosis, is a valuable tool in differentiating PE in patients with dyspnea, such as pulmonary hypertension (PH), in real-world practice. Methods and Result : Between 2012 and 2019, 269 patients were enrolled based on specific criteria: 1) pulmonary artery systolic pressure >40 mmHg by TTE, 2) PE confirmed by chest contrast CT, and 3) TTE and CT conducted within a 72-hour interval. The study population was categorized into two groups: PE (n=149) and Non-PE (n=120). In the mitral inflow Doppler parameters, the PE group exhibited significantly lower mitral E velocity. The cutoff value of mitral E velocity (AUC 0.865, 95% CI 0.81-0.92, pConclusion : This study suggests that mitral E velocity is an independent predictor for diagnosing PE. The cutoff value of mitral E velocity is a practical tool for ruling out PE in patients with PH in real-world practice.
- Open Access
- 7 April 2023
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 34 (4) , 288-290
Large right coronary artery aneurysm with small fistula to coronary sinus: multimodality imaging
- 7 April 2023
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 34 (4) , 288-290
Open AccessLarge right coronary artery aneurysm with small fistula to coronary sinus: multimodality imaging